Delavirdine
Delavirdine
Delavirdine (pronounced: /ˌdɛləˈvɪərdaɪn/) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV infection. It is marketed under the trade name Rescriptor.
Etymology
The name "Delavirdine" is derived from the chemical name 2',3'-dideoxy-3'-hydroxymethyl-4,6-dichloro-5-fluoropyrimidine. The prefix "Dela-" is a contraction of "dideoxy", and "-virdine" is a common suffix for non-nucleoside reverse transcriptase inhibitors.
Usage
Delavirdine is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It works by inhibiting the reverse transcriptase enzyme, thereby preventing the virus from multiplying in the body.
Related Terms
- Antiretroviral therapy
- HIV
- Reverse transcriptase inhibitor
- Non-nucleoside reverse transcriptase inhibitors
Side Effects
Common side effects of Delavirdine include skin rash, fatigue, headache, and nausea. Severe side effects may include liver damage and severe skin reactions.
Contraindications
Delavirdine should not be used in patients with severe liver disease or in combination with certain other medications due to the risk of drug interactions.
See Also
External links
- Medical encyclopedia article on Delavirdine
- Wikipedia's article - Delavirdine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski